The results by Arezes et al. showed that hepcidin‐induced hypoferremia was a defense mechanism against pathogens dependent upon iron and revealed hepcidin agonists as potential therapy to improve infection outcome for patients with HH or thalassemia 103. This evidence concerns the gene HAMP and thalassemia.